The analysis of mucosal immune responses induced by intranasal administration of an inactivated influenza virus vaccine in human.

The analysis of mucosal immune responses induced by intranasal administration of an inactivated influenza virus vaccine in human. - The analysis of antibody, B and T cell responses induced by intranasal administration of an inactivated whole-virus vaccine (A/H5N1) in human, and the characterization of secretory IgA antibodies in nasal mucus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008279

Enrollment

Registered

2012-06-28

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Intranasal administration of an inactivated whole-virus vaccine (A/H5N1, 45ug HA/dose) is performed twice with a 3 week interval. About a half year later, the same vaccination will be performed once m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adult volunteers who are interested in the open recruitment for our study, and agree with our study contents, as confirmed by giving their informed consent before the onset of the study.

Exclusion criteria

Exclusion criteria: 1. Volunteers with a fever at the time of planned vaccination. 2. Volunteers with serious acute diseases. 3. Volunteers considered inappropriate to be inoculated vaccine.

Design outcomes

Primary

Measure	Time frame
Neutralization, HI, and HA-specific antibody titers before and after intranasal vaccination. The proportion of memory B cell or plasma cell in peripheral blood mononuclear cells, and the cytokine profile. The analysis of the antibody repertoire induced by the intranasal vaccination. The characterization of secretory IgA antibodies in nasal mucus. Survey on side reaction after vaccination.	—

Countries

Japan

Contacts

Public ContactHideki Hasegawa

National Institute of Infectious Diseases Department of Pathology

hasegawa@nih.go.jp03-5285-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026